<DOC>
	<DOCNO>NCT02007070</DOCNO>
	<brief_summary>This study do evaluate safety efficacy pembrolizumab ( MK-3475 ) participant advance non-small cell lung cancer ( NSCLC ) tumor positive program cell death ligand 1 ( PD-L1 ) : hypothesis treatment pembrolizumab result clinically meaningful Overall Response Rate ( ORR ) .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Participants With Advanced Non-small Cell Lung Cancer ( MK-3475-025/KEYNOTE-025 )</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis nonsmall cell lung cancer ( NSCLC ) PDL1 positive per central laboratory review At least one measurable lesion . Radiographic progression NSCLC treatment platinumcontaining doublet Stage IIIB/IV recurrent disease Eastern Cooperative Oncology Group ( ECOG ) Performance Scale 0 1 Adequate organ function Systemic cytotoxic chemotherapy , biological therapy , major surgery within 3 week first dose trial treatment Systemic steroid therapy within 3 day prior first dose trial treatment form immunosuppressive medication Expected require form systemic localize antineoplastic therapy trial History prior malignancy , exception basal cell carcinoma skin , superficial bladder cancer , squamous cell carcinoma skin , situ cancer Active central nervous system ( CNS ) metastases and/or carcinomatous meningitis Active autoimmune disease document history autoimmune disease syndrome require systemic steroid immunosuppressive agent Prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody Concurrent past history interstitial lung disease Pregnant breastfeeding , expect conceive father child within project duration study , start screen visit 120 day last dose pembrolizumab</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>